Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ayvakit Rollover Study in Systemic Mastocytosis
NCT06748001Phase 4Recruiting
- Sponsor
- Blueprint Medicines
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of avapritinib in systemic mastocytosis (SM), sponsored by Blueprint Medicines. Primary endpoint: Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and Adverse Events (AEs) leading to Discontinuation at 4 years. Started Nov 2024; status: recruiting.
02
Drugs
avapritinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT06748001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748001.